UnknownNCT05956132
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies
Studying Calpain-3-related limb-girdle muscular dystrophy R1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IRCCS San Camillo, Venezia, Italy
- Principal Investigator
- RITA BARRESI, DRIRCCS SAN CAMILLO
- Intervention
- retrospective study(other)
- Enrollment
- 50 enrolled
- Eligibility
- All sexes
- Timeline
- 2023 – 2025
Study locations (2)
- San Camillo Irccs, Venice-Lido, VE, Italy
- IRCCS San Camillo, Venice-Lido, Italy
Collaborators
IRCCS Fondazione Stella Maris · Istituto Giannina Gaslini · Ospedale Policlinico San Martino · Universita di Verona · Azienda Ospedaliera Universitaria Senese · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05956132 on ClinicalTrials.govOther trials for Calpain-3-related limb-girdle muscular dystrophy R1
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05618080LGMD R1 Natural History StudyVirginia Commonwealth University
- RECRUITINGPHASE1, PHASE2NCT05230459A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)AskBio Inc
- ENROLLING BY INVITATIONNCT04989751A Multicenter Phenotype-Genotype Analysis of LGMD Patients in ChinaHuashan Hospital
See all trials for Calpain-3-related limb-girdle muscular dystrophy R1 →